WINSUNBIO
839729
HIGO
872351
DRIVE
838275
4
Shanghai Menon Animal Nutrition Technology
301156
5
Nanjing Railway New Technology
301016
CN Stock MarketDetailed Quotes
688506 Sichuan Biokin Pharmaceutical
- 250.25
- +3.26+1.32%
Market Closed Apr 3 15:00 CST
100.35BMarket Cap27.07P/E (TTM)
251.58High241.01Low11.35KlotVolume246.80Open246.99Pre Close280.54MTurnover1.23%Turnover Ratio27.07P/E (Static)401.00MShares254.0052wk High25.82P/B23.04BFloat Cap113.8952wk Low296.39Limit Up92.07MShs Float254.00Historical High197.59Limit Down4.28%Amplitude28.75Historical Low--Dividend TTM247.16Avg Price5.67KlotAsk--Div YieldTTM100Lot Size4.82KlotBid
Sichuan Biokin Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 936.31%5.82B | 1,399.22%5.66B | 1,685.19%5.55B | 4,325.45%5.46B | -20.11%561.87M | -21.37%377.7M | 2.06%311.04M | 1.74%123.43M | -11.73%703.28M | -21.75%480.34M |
| Operating revenue | 936.31%5.82B | 1,399.22%5.66B | 1,685.19%5.55B | 4,325.45%5.46B | -20.11%561.87M | -21.37%377.7M | 2.06%311.04M | 1.74%123.43M | -11.73%703.28M | -21.75%480.34M |
| Total operating cost | 38.04%1.9B | 44.60%1.36B | 15.71%759.99M | 29.87%386.89M | 31.36%1.37B | 26.45%943.85M | 43.32%656.84M | 65.18%297.91M | 8.26%1.05B | 7.13%746.41M |
| Operating cost | 15.31%264.39M | 21.07%175.79M | -0.81%111.4M | 25.75%58.92M | -1.48%229.28M | -4.02%145.2M | 29.79%112.3M | 56.72%46.85M | 17.71%232.74M | 6.43%151.29M |
| Operating tax surcharges | 9.77%11.5M | 45.60%7.89M | 28.78%6.2M | 127.81%3.25M | -23.34%10.48M | -40.62%5.42M | -12.38%4.81M | -36.67%1.43M | -3.29%13.67M | -16.98%9.12M |
| Operating expense | -14.58%214.56M | -13.17%156.05M | -24.07%106.99M | 0.54%58.03M | -22.54%251.19M | -20.83%179.72M | -3.14%140.89M | 4.98%57.72M | -17.12%324.3M | -25.58%227.01M |
| Administration expense | 63.22%190.48M | 32.73%117.35M | 28.63%71.29M | 1.14%27.18M | 48.26%116.7M | 47.97%88.41M | 46.16%55.42M | 48.70%26.87M | 3.35%78.71M | 8.07%59.75M |
| Financial expense | -1,188.91%-226.1M | -256.79%-23.99M | -860.43%-80.41M | -251.96%-9.26M | -5.70%20.76M | -2.20%15.3M | 9.24%10.57M | 40.32%6.09M | 154.18%22.02M | 168.15%15.65M |
| -Interest expense (Financial expense) | 72.31%42.52M | 50.32%27.8M | 32.82%16.65M | 12.14%7.14M | 9.78%24.68M | 15.42%18.49M | 25.85%12.53M | 42.72%6.37M | 158.64%22.48M | 179.95%16.02M |
| -Interest Income (Financial expense) | -3,513.53%-206.09M | -2,876.62%-130.18M | -2,905.23%-84.94M | -3,673.16%-21.01M | -643.96%-5.7M | -660.04%-4.37M | -631.01%-2.83M | -161.13%-556.88K | -61.45%-766.6K | -140.94%-575.4K |
| Research and development | 93.34%1.44B | 82.76%931.7M | 63.61%544.53M | 56.52%248.77M | 98.98%746.23M | 79.77%509.8M | 92.14%332.83M | 124.47%158.94M | 34.61%375.02M | 59.82%283.59M |
| Credit Impairment Loss | -134.02%-2.19M | -76.27%1.48M | -43.49%968.47K | -115.45%-263.11K | 183.82%6.44M | 313.08%6.22M | 221.57%1.71M | 408.63%1.7M | -356.32%-7.69M | -208.23%-2.92M |
| Asset Impairment Loss | -49.12%-19.35M | -23.55%-11.9M | -50.69%-9.22M | -23.87%-5.86M | -161.45%-12.98M | -145.14%-9.63M | -146.81%-6.12M | -374.12%-4.73M | 12.44%-4.96M | -13.62%-3.93M |
| Other net revenue | ||||||||||
| Fair value change income | --11.44M | --11.44M | --13.56M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Invest income | 493,205.27%19.23M | 493,205.27%19.23M | ---- | ---- | --3.9K | --3.9K | --3.9K | --3.9K | ---- | ---- |
| Asset deal income | -100.27%-401.66 | ---- | ---- | ---- | 853.26%146.39K | 853.26%146.39K | 853.26%146.39K | 853.26%146.39K | -308.89%-19.43K | -308.89%-19.43K |
| Other revenue | -10.31%44.66M | -9.66%31.75M | 345.67%30.28M | 233.64%4.21M | -27.01%49.79M | 49.71%35.15M | -66.07%6.79M | -93.14%1.26M | 0.44%68.21M | -59.35%23.48M |
| Operating profit | 617.16%3.98B | 914.18%4.35B | 1,506.63%4.83B | 2,981.04%5.07B | -167.48%-769.38M | -114.17%-534.25M | -149.76%-343.25M | -326.22%-176.09M | -183.49%-287.63M | -996.27%-249.46M |
| Add:Non operating Income | -32.87%1.54M | -75.59%558.29K | -97.65%53.38K | -98.32%17.93K | 3,461.65%2.3M | 4,523.39%2.29M | 4,820.73%2.27M | 2,852.26%1.07M | -57.25%64.62K | -57.98%49.48K |
| Less:Non operating expense | 17.42%2.28M | -62.26%652.37K | 2.88%639.25K | -63.18%145.65K | 28.89%1.94M | 25.07%1.73M | -53.09%621.36K | -63.66%395.53K | -51.90%1.5M | -50.70%1.38M |
| Total profit | 617.31%3.98B | 915.01%4.35B | 1,513.24%4.83B | 2,991.97%5.07B | -166.03%-769.01M | -112.81%-533.7M | -146.27%-341.61M | -314.05%-175.42M | -176.79%-289.07M | -885.76%-250.79M |
| Less:Income tax cost | 2,256.36%270.65M | 1,629.45%284.32M | 1,314.64%161.39M | 891.75%68.04M | 271.57%11.49M | -132.85%-18.59M | -1,210.80%-13.29M | -367.30%-8.59M | -50.60%-6.69M | -229.45%-7.98M |
| Net profit | 575.02%3.71B | 889.23%4.07B | 1,521.28%4.67B | 3,100.16%5.01B | -176.40%-780.5M | -112.15%-515.11M | -138.43%-328.32M | -265.99%-166.83M | -182.40%-282.38M | -954.86%-242.81M |
| Net profit from continuing operation | 575.02%3.71B | 889.23%4.07B | 1,521.28%4.67B | 3,100.16%5.01B | -176.40%-780.5M | -112.15%-515.11M | -138.43%-328.32M | -265.99%-166.83M | -182.40%-282.38M | -954.86%-242.81M |
| Net profit of parent company owners | 575.02%3.71B | 889.23%4.07B | 1,521.28%4.67B | 3,100.16%5.01B | -176.40%-780.5M | -112.15%-515.11M | -138.43%-328.32M | -265.99%-166.83M | -182.40%-282.38M | -954.86%-242.81M |
| Earning per share | ||||||||||
| Basic earning per share | 574.36%9.25 | 892.19%10.14 | 1,519.51%11.64 | 3,071.43%12.48 | -150.00%-1.95 | -91.04%-1.28 | -115.79%-0.82 | -223.08%-0.42 | -178.57%-0.78 | -1,016.67%-0.67 |
| Diluted earning per share | 574.36%9.25 | 892.19%10.14 | 1,519.51%11.64 | 3,071.43%12.48 | -150.00%-1.95 | -91.04%-1.28 | -115.79%-0.82 | -223.08%-0.42 | -178.57%-0.78 | -1,016.67%-0.67 |
| Other composite income | 64.19%-597.09K | 747.31%15.59M | 395.52%7.86M | 56.28%-1.45M | -4,972.93%-1.67M | -183.46%-2.41M | -463.35%-2.66M | -4,383.76%-3.31M | 110.16%34.22K | 2,305.20%2.89M |
| Other composite income of parent company owners | 64.19%-597.09K | 747.31%15.59M | ---- | 56.28%-1.45M | -4,972.93%-1.67M | -183.46%-2.41M | ---- | -4,383.76%-3.31M | 110.16%34.22K | 2,305.20%2.89M |
| Total composite income | 573.93%3.71B | 888.57%4.08B | 1,512.24%4.67B | 3,040.95%5B | -177.03%-782.17M | -115.70%-517.51M | -141.65%-330.98M | -273.89%-170.14M | -181.42%-282.34M | -947.78%-239.92M |
| Total composite income of parent company owners | 573.93%3.71B | 888.57%4.08B | 1,512.24%4.67B | 3,040.95%5B | -177.03%-782.17M | -115.70%-517.51M | -141.65%-330.98M | -273.89%-170.14M | -181.42%-282.34M | -947.78%-239.92M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- | -- |
| Auditor | -- | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.